Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP VET for veterinary use

EQS-News: Viromed Medical AG / Key word(s): Alliance/Contract Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP VET for veterinary use 10.04.2025 / 13:50 CET/CEST The issuer is solely responsible for the content of this announcement. Viromed Medical AG: Exclusive distribution partnership with AMAMUS Vet for the cold plasma medical device ViroCAP VET for veterinary use

Pinneberg, April 10. April 2025 - Viromed Medical AG ("Viromed", ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensive care medicine and air disinfection, and Lang Life Sciences GmbH, with its brand and veterinary platform AMAMUS Vet have signed an exclusive agreement to market Viromed's cold plasma medical device ViroCAP for use in veterinary medicine in Germany, Austria, and Switzerland.

Lang Life Sciences obtains exclusive rights to distribute ViroCAP VET for the veterinary treatment of skin infections, eczema, allergic skin reactions, bite wounds and other skin diseases in animals. The company will purchase a minimum volume of 1,000 ViroCAP devices over the first 12 months and will market and distribute them under the umbrella brand AMAMUS Vet in the DACH region. Deliveries will begin at the end of August. From this date, AMAMUS Vet will exclusively distribute ViroCAP VET in the cold plasma segment.

"Our aim is to utilize innovative products to reduce the use of antibiotics in veterinary medicine and to enable the most pain-free therapies possible for animals," says Jan Lang, founder and Managing Director of Lang Life Sciences GmbH. "This is why we have used cold plasma technology since 2018. The technology has the properties of a digital antibiotic while also preventing and treating viral infections. In scientific studies, Viromed's ViroCAP has shown a superior profile in the effective, painless and, in particular, contactless treatment of dermatological diseases. We are very pleased to be able to expand our portfolio with this innovation, which has the potential to reduce millions of doses of antibiotics in veterinary medicine every year."